COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

A Phase 2 Study of PacritiniB for Patients with BiochemicaL RelApse after Definitive Treatment for ProStaTe Cancer

Protocol No
IIT-KILARI-J31001-BLAST
Principal Investigator
Deepak Kilari
Phase
II
Summary
The purpose of this study is to test the effectiveness of a new drug called Pacritinib. Researchers would also like to study how Pacritinib slows down the time until cancer progression. They would also like to assess the safety and toxicity of Pacritinib and see how it compares with standard of care treatments. Pacritinib is investigational in this study, meaning it has not been approved by the FDA for the treatment of prostate cancer. In addition, although Pacritinib has been studied to treat other cancers, it has not previously been tested in other clinical trials as a treatment for prostate cancer.
Description
This project is being done to test the effectiveness of a new drug called Pacritinib.
Researchers would also like to study how Pacritinib slows down the time until cancer
progression and assess its safety and tolerability.
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL